The Lynx Group

October 2020, Vol 11, No 5

Nivolumab (Opdivo) is forging a new role in gastroesophageal cancers, according to results of 3 phase 3 clinical trials indicating that nivolumab as first-line therapy or adjuvant therapy can improve survival in patients with gastric and gastroesophageal junction (GEJ) cancer. These results are a “paradigm shift” for these patients, but questions remain, suggested several experts who discussed these results at the 2020 of the European Society for Medical Oncology (ESMO) virtual meeting.
Read Article

A real-world analysis showed that adjuvant immunotherapy in patients with stage III melanoma improved survival, but that only approximately 33% of eligible patients received such adjuvant therapy after ipilimumab (Yervoy) was approved by the FDA for this indication.
Read Article

Cholangiocarcinoma (CCA) is a rare type of cancer that arises from the intrahepatic or extrahepatic biliary ductal epithelium, accounting for approximately 10% to 15% of all primary hepatic malignancies. CCA is classified as intrahepatic or extrahepatic CCA. In the United States, the incidence of CCA has been rising consistently since 1973.
Read Article

Patients with “early-onset cancer”—that is, cancers that typically do not occur in younger adults (aged 18-39)—had a significantly higher rate of germline mutations than patients with the “young adult cancers” that are typically seen in this age-group (21% vs 13%, respectively; P = .002), according to results of a new study. The results were presented at the 2020 AACR virtual annual meeting and were highlighted at a meeting press cast.
Read Article

Treatment with the PD-1 inhibitor pembrolizumab (Keytruda) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with brentuximab vedotin (Adcetris), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
Read Article

Many cancer vaccines have been studied, but thus far the search has been unsuccessful. Results from a new study suggest that the combination of a messenger (mRNA)-based personalized cancer vaccine (known as RO7198457) plus the PD-L1 inhibitor atezolizumab (Tecentriq) shows promise for the treatment of advanced cancer. The results of the phase 1b clinical trial were presented at the 2020 AACR virtual annual meeting.
Read Article

Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit. The discussion was moderated by Clifford Goodman, PhD, Senior Vice President, Comparative Effectiveness Research, the Lewin Group.
Read Article

Value-based or alternative payment models have yet to deliver the cost-savings in oncology hoped for when these models were proposed, said experts at the September 2020 National Comprehensive Cancer Network Oncology Policy Summit during a panel discussion on best practices for value-based agreements.
Read Article

Page 3 of 3

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: